Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Suven Life Sciences announces Top-Line Results of SUVN-502 (Masupirdine) Phase 2A Study in Patients with Moderate Alzheimer's Disease (AD)

Posted On: 2019-11-30 16:58:51


SUVN-502 did not meet the pre-specified primary endpoint

Meaningful improvements and potential beneficial effects on cognitive function, behavioral and neuropsychiatric end points were emerged based on subgroup analyses.

SUVN-502 was safe and well tolerated with no significant adverse events

Suven Life Sciences announces top-line results from its Phase 2A proof of concept study evaluating the efficacy, safety and tolerability of Masupirdine (SUVN-502). The first of its kind trial which focused on advanced stage AD patients (moderate AD) who are currently treated with standard of care Donepezil and Memantine. The unique triple-therapy (Masupirdine+ Donepezil+ Memantine) design was based on efficacy results in pre-clinical cognition models in which masupirdine enhances the effects of combined treatment with Donepezil and Memantine.

The primary efficacy endpoint of the trial is change from baseline to Week 26 in ADAS-Cog 11 score. The secondary outcome measures are MMSE, CDR-SB, ADCS-ADL, NPI, C-SDD, safety and tolerability assessment.

Findings of this Phase 2A study:

- Masupirdine (SUVN-502) is safe and well tolerated without significant adverse events.

- Triple therapy of Masupirdine (SUVN-502) with Donepezil and Memantine proof of concept phase 2 study missed its pre-specified primary endpoint.

- Subgroup analyses on cognition, function, behavioral, neuropsychiatric inventory and secondary endpoints revealed interesting, statistically significant and potentially beneficial data sets.

- Potential beneficial effects and statistically significant results with Masupirdine treated groups on cognition emerged upon considering combinations of Patients Age, Memantine regimen, Memantine plasma concentration, Memantine treatment duration and Alzheimer's disease duration.

- Sub-population of Masupirdine treated patients showed significant improvement and statistically significant reduction in the behavioral symptoms in the domains of agitation / aggression and delusions /hallucination as assessed by the NPI subscale scores.

- Detailed study outcomes of the above findings will be presented through one oral and six poster presentations at Clinical Trials on Alzheimer's Disease (CTAD) being held at San Diego from 4th - 7th December 2019.

We are very disappointed with the outcome of this trial but the findings present an important step forward in further exploration of the potential therapeutic effects of Masupirdine (SUVN-502) in Alzheimer's Disease (AD) and Behavioral & Psychological Symptoms in Dementia (BPSD). We will work with regulators and potential partnering companies in the design and conduct of future studies for further exploration of the potential of Masupirdine (SUVN-502) says Venkat Jasti, CEO of Suven.

Shares of SUVEN LIFE SCIENCES LTD. was last trading in BSE at Rs.314.05 as compared to the previous close of Rs. 312.75. The total number of shares traded during the day was 52597 in over 1718 trades.

The stock hit an intraday high of Rs. 317.6 and intraday low of 309.85. The net turnover during the day was Rs. 16529894.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

MT Educare Limited reports earnings for FY2020

HCL Technologies Ltd board to consider Q2, H1FY21 results and interim dividend on Oct 16, 2020

SBI to consider raising of Rs. 5000 crores

Reliance Retail Ventures Ltd receives subscription of ₹. 7500 crore from Silver Lake

Ujjivan Small Finance Bank makes a foray into Small Commercial Vehicle Finance

Escorts - Kubota JV starts commercial production of Kubota Tractors

NALCO and NRL sign MOU for long term supply of CP Coke

Ugro Capital Ltd receives Corporate Agency License from IRDAI

NCL Industries Ltd terminates JV agreement with Qingdao Xinguangzheng Steel Structure Company Ltd

Equitas Small Finance Bank Ltd reduces size of equity issue

Narendra Investments (Delhi) Ltd to foray into speciality and fine chemicals business, change name

This festive season, be ready to ruffle up some feathers with Fastrack x Ananya Panday

Tata Chemicals wins 'ICC Acharya P.C Ray Award for Development of Indigenous Technology'

Make your kitchen plastic-free with Glass Storage containers

CRISIL upgrades ratings of Solara Active Pharma Sciences Ltd

Canara Bank board to raise Rs. 2000 crore through QIP

SBI Card launches new brand campaign 'Contactless Connections'

RBI grants in-principle authorisation to set-up and operate Bharat Bill Payment Operating Unit to Vakrangee Ltd

Asian Granito India Ltd eyes robust sales growth from 'Bharat' markets

United Drilling Tools Limited's Equity share to list on National Stock Exchange of India Limited

Dr. Reddy's announces the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in the U.S. Market

Granules India Limited announces US FDA approval of Naproxen Sodium and Diphenhydramine Hydrochloride Tablets, 220 mg/25 mg (OTC)

Hitachi ABB Power Grids energizes first stage of Raigarh-Pugalur 800 kV UHVDC transmission link

Zydus Cadila receives final approval from USFDA for Dimethyl Fumarate Delayed-Release Capsules

Meera Industries Ltd receives export order of $140,000

Pritish Nandy Communications's show for Amazon gets International Emmy Nomination

Cipla receives final approval for generic version of Biogen IDEC Inc.'s Tecfidera®

GMR Infrastructure Ltd announces divestment of Group's entire stake in Kakinada SEZ Limited

Yedeshi Aurangabad BOT Project receives completion certificate

ONGC to soon resume operations in Hazira Plant after fire

CRISIL reaffirms rating of BASF India Limited's NCDs

Gayatri Projects Limited receives contract from OMC

RITES Limited secures contracts for Rs. 205.85 crore

Kotak Partners Delhi Capitals, Launches MyTeam Card - Special Cricket Edition Debit & Credit Cards

GAIL maintains CNG and D-PNG supplies despite upstream disruptions

Nestle India Ltd board to consider Q3 results on Oct 23, 2020

The Ramco Cements Ltd enters into MoU with Government of Tamil Nadu for establishment of an Apex Skill Development Centre at Ariyalur

Marico Limited divests stake in Revofit

maurices Partners with TCS to Build Greenfield IT Ecosystem for its Growth and Transformation

Mahindra & Mahindra increases its stake to 74.97% in Sampo Rosenlew

Ramco Systems signs agreement with United Arab Shipping Company Limited

Dynamatic receives contract with Boeing in support of T-7A Red Hawk

J. Kumar Infraprojects Ltd receives LOA from MMRDA, DMRC

Kotak Partners Mumbai Indians, Launches MyTeam Card - Special Cricket Edition Debit & Credit Cards

Edelweiss Tokio Life to focus on 'Impacting Lives'

Mindspace Business Parks REIT first real estate entity from India to pledge commitment to the Climate Group's EV100 initiative

Panacea Biotec announces successful completion of Phase I / II study of its novel, Tetravalent recombinant chimeric Dengue candidate vaccine, DengiAll

Tata Elxsi Opens Global Engineering Center (GEC) for Schaeffler's mobility solutions

Jindal Stainless Limited clarifies on pledged shares with SBICAP

Jindal Stainless Limited clarifies on pledged shares







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019